Finerenone for albuminuria in patients with diabetic nephropathy

• Autores: Yanhuan Feng, Xiaoxi Zeng, Ping Fu
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 3, 2016, págs. 305-306
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • To the Editor Dr Bakris and colleagues1 evaluated the safety and efficacy of dual blockade of the renin-angiotensin-aldosterone system by adding the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker in patients with diabetic nephropathy. The authors stated that the addition of finerenone resulted in improvement in the urinary albumin-creatinine ratio (UACR) compared with placebo. We have a number of concerns about the study.